The Team

The Fairplay Ventures executive team has come together to commercialize a once in a lifetime opportunity.  Not since the days of prohibition has an “Unlock” taken place for such a massive wave of growth.  The passing of the Farm Bill in 2018 was just the beginning of a multi -decade run with one of the earth’s most versatile and beneficial plants.  To capitalize on this opportunity a world class team has been put together complemented by a hand-picked advisory board to ensure the best path forward.

Chris
Furno

CEO

Chris Furno is an entrepreneur, investor and global strategic connector.  Chris’s most recent accomplishments include the global expansion of  Lottery.com.  While working with Lottery Chris played a pivotal role in both the  Series A round of funding and also key sports marketing efforts to accelerate growth and maximize valuation.

Dave
Johnson

President

Dave Johnson brings a unique blend of corporate, private equity and start-up experience to the team.  Dave joins Fairplay Ventures from his role as President of Curaleaf Hemp.  Prior to Curaleaf Dave enjoyed various consumer product & services businesses in which value creation and exit were realized.  Dave started his career at Frito-Lay where he spent 20 years with rapidly escalating responsibilities in the areas of sales and operations.

Raffy
Ohannesian

CFO

Raffy Ohannesian is a well accomplished Finance and management executive with significant experience in M&A, due diligence, valuation, turnaround, restructuring, corporate finance and IT systems.  Prior to Fairplay Raffy served as CFO and board advisor for various companies in California, supporting privately held businesses and PE / VC portfolio companies that are experiencing significant growth, seeking institutional funding or experiencing financial / operational distress.  He is an experienced executive raise capital for start-up and early growth companies, having managed all financial, legal, regulatory and investor relations matters for one of the first Security Token Offerings in the US.

Advisory Board

Dr. Kris Nichols leads MyLand Company’s research initiatives, including a 4-acre, multi-crop,random block design study at the University of Arizona’s experimental facility in Maricopa, Arizona. She was Rodale Institute’s Chief Scientist for 3.5 years and a Research (Soil)Microbiologist with the USDA, Agricultural Research Service (ARS) for 14 years. Kris has B.S.degrees in Plant Biology and Genetics and Cell Biology from the University of Minnesota, anM.S. in Environmental Microbiology from West Virginia University, and a Ph.D. in Soil Science from the University of Maryland. Her focus is addressing current and future agricultural needs by building upon a soil health foundation to identify biological tools to enhance soil health, water and nutrient use efficiencies, pest and disease management, and mitigate climate change.

Tony DiMatteo is the co-founder and CEO of Lottery.com, a four year old courier service operating in multiple states, enabling consumers to play state sanctioned lottery games directly from their mobile phones. Lottery.com is also the largest provider of lottery data in the world with clients including Google and Amazon. The company has worked with regulators and industry leaders to help legitimize lottery courier services in the United States. DiMatteo is responsible for global initiatives and the development and execution of the company’s long-term strategy. He is a sought after thought leader, and his approach to social impact, entrepreneurship, blockchain, and the gaming industry has been covered in The Wall Street Journal, VentureBeat, TechCrunch, Inc. and more. Tony has also been a featured guest speaker at Tony Robbins’ Platinum Finance and Peter Diamand is’ A360 events speaking on the future of fundraising.

Brian I. Rini, MD, FASCO, is the Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center (VICC) and Ingram Professor of Medicine at Vanderbilt University, where he leads kidney cancer clinical research efforts and the expansion of oncology clinical research operations. His research activities include over 200 publications extensively covering genitourinary cancer, most notably renal cell carcinoma. Dr. Rini has been lead investigator of several phase 3 clinical trials which have led to FDA approval. He has spoken at numerous seminars and invited lectureships, locally, nationally, and internationally, on genitourinary cancers and their treatments. He is a member of ASCO, KCA (Kidney Cancer Association)and SITC (Society for Immunotherapy of Cancer) with leadership positions in these organizations. He recently completed a term as a member and immediate past Chair of the Oncologic Drugs Advisory Committee (ODAC).